RASSF1 and non-small cell lung carcinoma: The authors have likewise demonstrated that the increase in IAP-2 content in the RASSF1A-depleted HBEC cells is exacerbated by gemcitabine, the administration of which should thus be less efficient to patients with NSCLC exhibiting RASSF1A promoter gene methylation.